-
-
表 1 抗结核药物分类
组别 药物分类 药物名称 1 一线口服药 异烟肼、利福平、乙胺丁醇、吡嗪酰胺、利福喷丁、利福布丁 2 注射用药 链霉素、卡那霉素、阿米卡星、卷曲霉素 3 氟喹诺酮类药 氧氟沙星、左氧氟沙星、莫西沙星 4 二线口服抑菌药 乙硫异烟胺、丙硫异烟胺、环丝氨酸、特立齐酮、对氨基水杨酸钠、对氨基水杨酸异烟肼、氨硫脲 5 疗效不确切药* 氯法齐明、利奈唑胺、阿莫西林克拉维酸钾、克拉霉素、亚胺培南 *指耐多药结核病治疗中疗效尚不确切的药物 -
[1] World Health Organization. Global tuberculosis control. Epidemiology, strategy, financing[EB/OL]. Genera: WHO, 2009. http://www.who.int/en/. [2] World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response[EB/OL]. Genera: WHO, 2010. http://www.who.int/en/. [3] Pandemic (H1N1) 2009-update 110[EB/OL]. Geneva: World Health Organization. http://www.who.int/en/. [4] 中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007-2008年)[R].北京: 人民卫生出版社, 2010. [5] Cho SN. Current issues on molecular and immunological diagnosis of tuberculosis[J]. Yonsei Med J, 2007, 48:347-359. doi: 10.3349/ymj.2007.48.3.347 [6] 中国防痨协会.耐药结核病化学治疗指南(2009)[J].中华结核和呼吸杂志, 2010, 33:485-497. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhjhhhx201007003 [7] Masjedi MR, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDR-TB patients with standardized regimens, lran, 2002-2006[J]. Int J Tuberc Lung Dis, 2008, 12:750-755. http://www.ingentaconnect.com/contentone/iuatld/ijtld/2008/00000012/00000007/art00011 [8] Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia:a retrospective cohort study[J]. Lancet, 2005, 365:318-326. doi: 10.1016/S0140-6736(05)17786-1 [9] Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis[J]. Science, 2005, 307:223-227. doi: 10.1126/science.1106753 [10] Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration[J]. Antimicrob Agents Chemother, 2006, 50:3543-3547. doi: 10.1128/AAC.00766-06 [11] Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant Tuberculosis[J]. N Engl J Med, 2009, 360:2397-2405. doi: 10.1056/NEJMoa0808427 [12] Gandhi NR, Shah NS, Andrews JR, et al. HIV infection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality[J]. Am J Respir Crit Care Med, 2010, 181:80-86. doi: 10.1164/rccm.200907-0989OC [13] Keshavjee S, Farmer PE. Picking up the pace-scale-up of MDR tuberculosis treatment programs[J]. N Engl J Med, 2010, 363:1781-1784. doi: 10.1056/NEJMp1010023 [14] Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis-critical steps for prevention and control[J]. N Engl J Med, 2010, 363:1050-1058. doi: 10.1056/NEJMra0908076 [15] Heller T, Lessells RJ, Wallrauch CG, et al. Communitybased treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal South Africa[J]. Int J Tuberc Lung Dis, 2010, 14:420-426. http://www.cabdirect.org/abstracts/20103102567.html
点击查看大图
表(1)
计量
- 文章访问数: 132
- HTML全文浏览量: 33
- PDF下载量: 17
- 被引次数: 0